10-K/A: Protagenic Therapeutics Files Amended 10-K, Cites Progress in Clinical Trials

Protagenic Therapeutics has filed an amendment to its annual report, highlighting the correction of an error and providing updates on its clinical trial progress for PT00114.

Summary

• Protagenic Therapeutics filed an amended 10-K report to correct an omission of an exhibit in the original filing.
• The company is focused on developing therapeutics for stress-related neuropsychiatric and mood disorders, with lead compound PT00114.
• PT00114 is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), which aims to dampen overactive stress responses.
• Preclinical models have shown PT00114's efficacy in animal models of depression, anxiety, substance abuse, and PTSD.
• The company commenced its first human trial for PT00114 on September 26, 2023, and announced the trial passed its safety milestone on February 13, 2024.
• The company anticipates announcing the complete results of the single-dose portion of the Phase I trial in the second quarter of 2024.
• Protagenic plans to re-submit an investigational new drug (IND) application before initiating the Phase IIa portion of the clinical study.
• The company's clinical program is led by Dr. Maurizio Fava, a world-leader in psychiatric disorders.
• The Phase I/IIa study is designed to evaluate the safety, tolerability, and early activity of PT100114 in healthy volunteers and patients with psychiatric illnesses.
• The company is targeting indications such as treatment-resistant depression, substance use disorder, generalized anxiety disorder, and post-traumatic stress disorder.
• The company had a net loss of $5,000,497 for the year ended December 31, 2023, compared to a net loss of $3,555,505 for the year ended December 31, 2022.
• As of December 31, 2023, the company had cash of $1,287,893 and working capital of $3,544,785.
• The company believes its cash resources will be sufficient to fund operations until approximately the end of the third quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is positive progress in clinical trials and a novel approach to treatment, the company's financial situation and internal control weaknesses raise concerns. The company's cash runway is limited, and it will need to raise additional capital to continue operations.

Positives

• The company's lead product candidate, PT00114, has shown promising results in preclinical studies.
• The company has commenced its first human trial for PT00114 and passed its safety milestone.
• The company has a strong intellectual property position with exclusive worldwide rights to PT00114.
• The company has a novel mechanism of action for PT00114, which may provide a differentiated side effect profile.
• The company has a well-known expert, Dr. Maurizio Fava, leading its clinical development program.
• The company has completed non-GLP Dose-Range-Finding toxicology studies of PT00114, showing it was well tolerated and safe.

Negatives

• The company has incurred significant operating losses since inception and expects to continue to incur losses.
• The company has a limited operating history and has not generated any product revenue.
• The company's cash resources are only sufficient to fund operations until approximately the end of the third quarter of 2024.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or difficulties.
• The company has no experience in commercializing any product and may need to rely on third parties for sales and marketing.
• The company's internal controls over financial reporting were not effective as of the end of the period covered by the report.

Risks

• The company's financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern.
• The company may not be able to obtain the capital necessary to fund its operations, which could lead to a reduction or cessation of operations.
• The company's product candidates may not be safe or effective, or receive regulatory approval.
• The company may experience delays or difficulties in the enrollment of subjects to its clinical trials.
• The company relies on third parties for various aspects of its business, including manufacturing and clinical trials.
• The company may not be able to gain market acceptance of its product candidates.
• The company may not be able to maintain its exclusive worldwide license to use and develop PT00114.
• The company's common stock is a Penny Stock subject to specific rules governing its sale to investors that could impact its liquidity.
• The market price of the company's common stock may be volatile.
• The company may experience dilution of their ownership interests because of the future issuance of additional shares of common stock.

Future Outlook

The company anticipates announcing the complete results of the single-dose portion of the Phase I trial in the second quarter of 2024 and plans to re-submit an IND application before initiating the Phase IIa portion of the clinical study. The company believes its cash resources will be sufficient to fund operations until approximately the end of the third quarter of 2024.

Management Comments

• Management concluded that, during the year-ended December 31, 2023, our internal controls and procedures were not effective to detect the inappropriate application of U.S. GAAP.
• Management identified the following material weaknesses set forth below in our internal control over financial reporting: 1. We lack the necessary corporate accounting resources to maintain adequate segregation of duties; and 2. We did not perform an effective risk assessment or monitor internal controls over financial reporting.

Industry Context

The document highlights the significant unmet need in the treatment of stress-related neuropsychiatric disorders, which is a major area of focus in the pharmaceutical industry. The company's approach of using a novel mechanism of action with TCAP is a departure from traditional methods and could potentially offer a new treatment option for patients.

Comparison to Industry Standards

• The document mentions several existing treatments for depression, anxiety, and addiction, including SSRIs, SNRIs, benzodiazepines, and opioid agonists/antagonists.
• The company's approach with TCAP is different from these existing treatments, which often have limited efficacy and significant side effects.
• The company's preclinical data suggests that PT00114 has a rapid onset of action and long-lasting effects, which could be a competitive advantage over existing treatments.
• The company is targeting a large patient population with significant unmet needs, which could lead to significant market penetration and sales if the product is successful.
• The company is competing with major international pharmaceutical companies and other institutions that have substantially greater financial, research and development, marketing and sales capabilities.

Corporate Governance

Legal Proceedings

• Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

Related Party Transactions

• The company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen.
• The company incurred $149,509 and $105,928 in expenses related to research and development services with Agenus Inc. during the years ended December 31, 2023 and 2022, respectively.
• The company incurred $106,754 and $105,801 in expenses related to research and development services with CTC North, GmbH during the years ended December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders may experience dilution of their ownership interests due to future issuance of additional shares.
• Shareholders may experience losses due to the volatility of the company's stock price.
• Employees may be affected by the company's financial instability and potential need to reduce operations.
• Customers (potential patients) may benefit from the development of new treatment options for stress-related disorders.
• Suppliers and creditors may be affected by the company's financial instability and potential need to reduce operations.

Next Steps

• The company plans to re-submit an investigational new drug (IND) application.
• The company anticipates announcing the complete results of the single-dose portion of the Phase I trial in the second quarter of 2024.
• The company plans to commence the multiple dose portion of the Phase I study for PT00114 in the second quarter of 2024.
• The company plans to initiate a Phase IIa study for PT00114 in the third quarter of 2024.

Key Dates

Keywords

PT00114, TCAP, neuropsychiatric disorders, clinical trials, depression, anxiety, substance abuse, PTSD, biopharmaceutical, drug development